No NHS Coverage for Janssen’s Spravato: NICE Denies Re-Appraisal of Esketamine for TRD
- A Half-Decade Battle Bears No Fruit for Janssen
- Janssen Hoped Head-to-Head Quietiapine Study Might Quiet NICE’s Concerns
- Implications for Psychedelic Therapies
Earlier this month, the National Institute for Health and Care Excellence (NICE), which stipulates which medical interventions are covered by England and Wales’ National Health Service (NHS), issued a statement that effectively brings Janssen’s ambitions to have its esketamine nasal spray (Spravato) product for treatment-resistant depression (TRD) reimbursed by the NHS in the UK’s most populous countries to a close.
After a half-decade of back-and-forth, the agency has again stood by its recommendation that Spravato not be covered by the state-backed health system. That original recommendation, delivered in 2020, revealed that the public body was not convinced by the product’s clinical data or cost-effectiveness.
The remit of this latest review, then, was “to consider whether any evidence presented would change the current recommendation”, NICE explained. It concluded that it would not...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks